HUP0303644A2 - Aldóz-reduktáz inhibitor hatású piridazinon-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Aldóz-reduktáz inhibitor hatású piridazinon-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0303644A2 HUP0303644A2 HU0303644A HUP0303644A HUP0303644A2 HU P0303644 A2 HUP0303644 A2 HU P0303644A2 HU 0303644 A HU0303644 A HU 0303644A HU P0303644 A HUP0303644 A HU P0303644A HU P0303644 A2 HUP0303644 A2 HU P0303644A2
- Authority
- HU
- Hungary
- Prior art keywords
- diabetic
- inhibitors
- aldose reductase
- compounds
- formula
- Prior art date
Links
- 239000003288 aldose reductase inhibitor Substances 0.000 title abstract 3
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 4
- 208000002249 Diabetes Complications Diseases 0.000 abstract 2
- 206010012655 Diabetic complications Diseases 0.000 abstract 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 2
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 abstract 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 abstract 1
- UUAVJCDYOHIIQW-UHFFFAOYSA-N 4-sulfonylpyridazin-3-one Chemical class O=C1N=NC=CC1=S(=O)=O UUAVJCDYOHIIQW-UHFFFAOYSA-N 0.000 abstract 1
- 102000016912 Aldehyde Reductase Human genes 0.000 abstract 1
- 108010053754 Aldehyde reductase Proteins 0.000 abstract 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 abstract 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 229930091371 Fructose Natural products 0.000 abstract 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
- 239000005715 Fructose Substances 0.000 abstract 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 abstract 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 abstract 1
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229940127088 antihypertensive drug Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 230000010030 glucose lowering effect Effects 0.000 abstract 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 abstract 1
- 108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 206010062198 microangiopathy Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A találmány (I) általános képletű új szulfonil-piridazinon-vegyületekre - a képletben A jelentése S, SO vagy SO2; R1 és R2jelentése egymástól függetlenül hidrogénatom vagy metilcsoport; és R3jelentése Het1, -CHR4Het1 vagy NR6R7-, ezeket a vegyületekettartalmazó gyógyászati készítményekre, és az ilyen vegyületek éskészítmények aldóz-reduktáz gátlására, szorbitkoncentrációcsökkentésére, és ezáltal fruktózkoncentráció csökkentésére és/vagydiabéteszes szövődmények, például diabéteszes neuropátia, diabéteszesretinopátia, diabéteszes nefropátia, diabéteszes kardiomiopátia,diabéteszes mikroangiopátia és diabéteszes makroangiopátia kezelésérevagy megelőzésére történő alkalmazására vonatkozik. A találmánytárgyát képezik továbbá gyógyászati készítmények és készletek, amelyekegy találmány szerinti (I) általános képletű aldóz-reduktáz inhibitorés egy szorbit-dehidrogenáz inhibitor kombinációját tartalmazzák, és afenti készítmények vagy készletek alkalmazása a fent említettdiabéteszes szövődmények megelőzésére vagy kezelésére. A találmánytárgyát képezik továbbá az (I) általános képletű aldóz-reduktázinhibitorok egyéb kombinációi, beleértve az NHE-1 inhibitorokkal;adenozin agonistákkal; glikogén-foszforiláz inhibitorokkal (GPI-k);szelektív szerotonin újrafelvétel inhibitorokkal (SSRI-k); g-aminovajsav (GABA) agonistákkal; antihipertenzív szerekkel; 3-hidroxi-3-metilglutaril-koenzim A-reduktáz inhibitorokkai (vasztatinok);foszfodiészteráz-5 (PDES) inhibitorokkal és glükózkoncentrációtcsökkentő vegyületekkel alkotott kombinációit is. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28005101P | 2001-03-30 | 2001-03-30 | |
| PCT/IB2002/000320 WO2002079198A1 (en) | 2001-03-30 | 2002-01-31 | Pyridazinone aldose reductase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0303644A2 true HUP0303644A2 (hu) | 2004-03-01 |
| HUP0303644A3 HUP0303644A3 (en) | 2008-06-30 |
Family
ID=23071435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0303644A HUP0303644A3 (en) | 2001-03-30 | 2002-01-31 | Pyridazinone-derivatives aldose reductase inhibitors, their use and pharmaceutical compositions containing them |
Country Status (43)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69722426T3 (de) | 1996-07-24 | 2015-05-07 | Warner-Lambert Company LLC (n.Ges. des Staates Delaware) | Isobutylgaba und dessen derivate zur schmerzbehandlung |
| ES2240657T3 (es) * | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
| JP2004528319A (ja) * | 2001-03-30 | 2004-09-16 | ファイザー・プロダクツ・インク | ピリダジノンアルドースレダクダーゼ阻害物質 |
| AU761191B2 (en) * | 2001-05-24 | 2003-05-29 | Pfizer Products Inc. | Therapies for tissue damage resulting from ischemia |
| DE60301324T2 (de) * | 2002-01-09 | 2006-05-24 | Pfizer Products Inc., Groton | Verfahren und zwischenprodukte für pyridazinone als mittel zur behandlung der zuckerkrankheit |
| US20040092522A1 (en) * | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US7419981B2 (en) * | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US6872833B2 (en) * | 2003-04-14 | 2005-03-29 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| ES2282062T1 (es) | 2004-06-04 | 2007-10-16 | Teva Pharmaceutical Industries Ltd. | Composicion farmaceutica que contiene irbesartan. |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| EP1769088A2 (en) * | 2004-06-30 | 2007-04-04 | Whitehead Institute For Biomedical Research | Novel methods for high-throughput genome-wide location analysis |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| RU2008127501A (ru) * | 2006-01-13 | 2010-02-20 | Вайет (Us) | Сульфонилзамещенные 1н-индолы в качастве лигандов 5-гидрокситриптаминовых рецепторов |
| WO2008001931A2 (en) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| JP2010043063A (ja) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
| CA2783699C (en) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Primary amine compounds for treating ocular disorders |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| CN104080451B (zh) * | 2011-09-15 | 2016-08-24 | 台北医学大学 | 吲哚异羟肟酸和吲哚啉异羟肟酸于治疗心脏衰竭或神经损伤的用途 |
| US9339542B2 (en) * | 2013-04-16 | 2016-05-17 | John L Couvaras | Hypertension reducing composition |
| BR112015026513A2 (pt) | 2013-04-17 | 2017-07-25 | Pfizer | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares |
| CN103739547B (zh) * | 2014-01-03 | 2015-09-02 | 沈阳药科大学 | 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法 |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| CA2982784A1 (en) * | 2015-04-14 | 2016-10-20 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| AU2017281082B2 (en) | 2016-06-21 | 2021-03-18 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and methods of use thereof |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| WO2018058109A1 (en) * | 2016-09-26 | 2018-03-29 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES |
| AU2018215678A1 (en) | 2017-02-06 | 2019-08-22 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN111065392B (zh) | 2017-07-28 | 2024-10-25 | 应用治疗公司 | 用于治疗半乳糖血症的组合物和方法 |
| CR20210328A (es) | 2018-11-21 | 2021-12-02 | Univ Case Western Reserve | Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta |
| CA3125765A1 (en) | 2019-01-18 | 2020-07-23 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| EP3966320A4 (en) | 2019-05-07 | 2023-10-25 | University of Miami | TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS |
| CN119954725A (zh) | 2019-05-31 | 2025-05-09 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
| MX2021014441A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
| WO2022120353A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| KR950001039B1 (ko) * | 1990-11-30 | 1995-02-08 | 가부시끼가이샤 쓰무라 | 크로몬 유도체 및 이 화합물을 유효성분으로 하는 아르도스 리덕타제 저해제 |
| AU658887B2 (en) | 1991-03-28 | 1995-05-04 | Pfizer Inc. | Pyridazinone acetic acids as aldose reductase inhibitors |
| US5834466A (en) | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
| TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| ID24373A (id) * | 1997-09-24 | 2000-07-13 | Orion Corp | Biester dari 1-oksa, aza dan tianaftelan-2-on sebagai inhibitor fosfolamban |
| FR2822827B1 (fr) * | 2001-03-28 | 2003-05-16 | Sanofi Synthelabo | Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant |
| JP2004528319A (ja) * | 2001-03-30 | 2004-09-16 | ファイザー・プロダクツ・インク | ピリダジノンアルドースレダクダーゼ阻害物質 |
| AU2002236131B2 (en) * | 2001-04-30 | 2005-04-14 | Pfizer Products Inc. | Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| DE60301324T2 (de) * | 2002-01-09 | 2006-05-24 | Pfizer Products Inc., Groton | Verfahren und zwischenprodukte für pyridazinone als mittel zur behandlung der zuckerkrankheit |
-
2002
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/en active IP Right Grant
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 EP EP04023150A patent/EP1491541B1/en not_active Expired - Lifetime
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active Expired - Fee Related
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-01-31 CA CA002442476A patent/CA2442476A1/en not_active Abandoned
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 EP EP02716247A patent/EP1373259B1/en not_active Expired - Lifetime
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 EP EP04023149A patent/EP1491540B1/en not_active Expired - Lifetime
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
-
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
-
2006
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0303644A2 (hu) | Aldóz-reduktáz inhibitor hatású piridazinon-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| BRPI0515012A (pt) | substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso | |
| Johnson et al. | Metabolic pathways for the activation of the antiretroviral agent 2', 3'-dideoxyadenosine in human lymphoid cells. | |
| WO2005007085A3 (en) | Pyrazolo pyrimidine derivatives and methods of use thereof | |
| NO20083523L (no) | Sammensetning for vaginal anvendelse | |
| BRPI0717510B8 (pt) | análogos de oligonucleotídeo cpg contendo análogos t hidrofóbicos com atividade imunoestimulatória intensificada e composição farmacêutica que os compreende | |
| SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
| UY31209A1 (es) | Uso de homo y copolimeros para la estabilización de formulaciones de principios activos | |
| NO20021751L (no) | Purinderivater | |
| EP1951729A4 (en) | OXYGEN-LINKED PYRIMIDINE DERIVATIVES | |
| NO20091509L (no) | Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter | |
| WO2007041130A3 (en) | Deazapurines useful as inhibitors of janus kinases | |
| BRPI0607661A2 (pt) | amplificação e clonagem de molécula de único dna usando amplificação de cìrculo rolante | |
| BRPI0416752B8 (pt) | composição farmacêutica, uso de um ou mais compostos, e, compostos | |
| NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
| AP2001002287A0 (en) | Purine derivatives. | |
| MXPA05014082A (es) | Acidos biariloximetilarenocarboxilicos. | |
| ATE541928T1 (de) | Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen | |
| MY154869A (en) | Composition for treating metabolic syndrome | |
| ATE552261T1 (de) | Pyrazol-ä1,5-aü pyrimidine als proteinkinasehemmer | |
| IL179883A0 (en) | 4,6-disubstituted pyrimidine derivatives and pharmaceutical compositions containing the same | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| DE60218751D1 (de) | Antitumor-zusammensetzungen enthaltend taxan-derivate | |
| BRPI0409742A (pt) | uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica | |
| DE60228722D1 (de) | Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater |